Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
127,672,444
-
Total 13F shares
-
91,611,954
-
Share change
-
+912,842
-
Total reported value
-
$4,141,780,605
-
Put/Call ratio
-
31%
-
Price per share
-
$45.22
-
Number of holders
-
203
-
Value change
-
+$32,677,050
-
Number of buys
-
123
-
Number of sells
-
81
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q2 2022
As of 30 Jun 2022 Apellis Pharmaceuticals, Inc. - Common Stock (APLS) had 203 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 91,611,954 shares of stock of the company.
Largest 10 holders included WELLINGTON MANAGEMENT GROUP LLP, Avoro Capital Advisors LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., EcoR1 Capital, LLC, STATE STREET CORP, Octagon Capital Advisors LP, JENNISON ASSOCIATES LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This table shows 204 institutional shareholders of the security as of 30 Jun 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.